Navigation Links
Acquisition of Devices, Methods and Intellectual Property Support Leadership Position in Regenerative Therapies
Date:7/22/2013

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- On Wednesday, July 17th, Celling Biosciences made an asset acquisition of devices, proprietary methods and intellectual property from Orogen Biosciences.  Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors and cytokines to optimize the most effective and efficient methods for providing therapeutic treatments with a patient's own tissue.   With this acquisition, Celling is furthering its position as a leader of point of care, autologous cell therapy. 

Celling is focused on the three pillars of regenerative medicine (cells, substrates, and signals) known to enhance the environment for tissue repair, regeneration, and revascularization.  The devices (OPC and ACE) and methods from Orogen provide physicians with access to a patient's own growth factors and proteins to support the healing cascade.  There is a growing body of evidence in the literature of the role growth factors play in optimizing the healing in multiple pathologies across medicine.  The OPC device allows physicians to process autologous plasma at the point of care to deliver concentrated growth factors when compared to currently marketed options.  The ACE device is a unique technology that produces an enriched preparation of growth factors without the presence of white blood cells, red blood cells or platelets. 

Additionally, Celling has acquired methods and devices for delivering allogeneic products to the veterinary market. Based on the short and long term success of these products in treating horses and canines in soft tissue repair, Celling will be well positioned to penetrate the veterinary market which is leading human efforts into the emerging market of regenerative medicine.   

Celling has begun the process of transitioning Orogen revenues, opening a Florida office and launching devices to the market within the next quarter.  "We believe this is a unique opportunity for Celling to keep building our product and services portfolio in the autologous space.  We continue to expand our registered nurse service model across the country anticipating the orchestrated event in cell therapy between physicians and technology providers.  This acquisition is another step in adding sophistication to the process," says Kevin Dunworth, CEO and Founder of Celling Biosciences. We had a number of companies approach us about acquiring Orogen's intellectual property but we were waiting on the right fit both culturally and philosophically based on who we believed to be a leader in cell therapy innovation.  "We are extremely excited about this development and are confident that Celling Biosciences has the vision to create significant value in the regenerative medicine space," says Ryan Brandt, President of Orogen.  

About Celling Biosciences
Celling Biosciences is an Austin, Texas based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.  Celling's product-offering focuses on autologous cell therapy and the devices and services that compliment these procedures.  For more information please visit: www.cellingbiosciences.com.

Troy Wilford
twilford@cellingbiosciences.com


'/>"/>
SOURCE Celling Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DTx to Introduce Data Acquisition Control & Robotic Instrument (DACRI) at Clinical Lab Expo in Houston, TX.
2. Techne Corporation Announces Acquisition Agreement
3. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
4. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
5. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
6. bioRASI Completes Acquisition of Ukrainian CRO
7. BGI-Shenzhen Completes Acquisition of Complete Genomics
8. Biotrial, a Leading Provider of Drug Development Services, Has Completed its Acquisition of Warnex Bioanalytical Services Division
9. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
10. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
11. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):